FINNENCE ▪ THE WIRE FILE
THE WIRE · № 56148
News▲ Bullish
Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder
KINDNews
DIRECTION▲ Bullish
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-09-29 22:45 UTC
LAST UPDATE2026-09-29 22:45 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Positive Phase III results support a potential label expansion, a direct pipeline value driver for the issuer.
Clinical win supports pipeline, not yet priced
CATALYST TO WATCH
Regulatory submission and approval decision
MAIN RISK
Approval or reimbursement may still fail
FULL DISPATCH
Study met its primary endpoint: timing of sleep onset shifted 37.1 minutes earlier versus placebo (p=0.022) 60% of HETLIOZ® treated participants shifted sleep at least 30 minutes earlier, compared to 15% of the placebo arm WASHINGTON, Sept. 29, 2026 /PRNewswire/ -- Vanda Pharmaceuticals...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
←CORRELATIONshares Healthcare
HealthPartners and Essentia to merge, creating one of Minnesota’s largest health systems2026-09-29 14:52 UTC
HealthPartners and Essentia to merge, creating one of Minnesota’s largest health systems2026-09-29 14:52 UTC
←CORRELATIONshares Healthcare
Health tech's dealmaking boom is back as firms chase scale and profitable growth2026-09-29 16:00 UTC
Health tech's dealmaking boom is back as firms chase scale and profitable growth2026-09-29 16:00 UTC
←CORRELATIONshares Healthcare
SU Group Narrows First-Half Operating Loss, Executes on Long-Term Strategy2026-09-29 20:00 UTC
SU Group Narrows First-Half Operating Loss, Executes on Long-Term Strategy2026-09-29 20:00 UTC
←CORRELATIONshares Healthcare
I AM ALS COMMUNITY POWERS HISTORIC REAUTHORIZATION OF ACT FOR ALS2026-09-29 21:12 UTC
I AM ALS COMMUNITY POWERS HISTORIC REAUTHORIZATION OF ACT FOR ALS2026-09-29 21:12 UTC
←CORRELATIONshares Healthcare
MN Attorney General promises public meetings on hospital merger and explains process2026-09-29 21:24 UTC
MN Attorney General promises public meetings on hospital merger and explains process2026-09-29 21:24 UTC
←CORRELATIONshares Healthcare
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes2026-09-29 22:00 UTC
Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes2026-09-29 22:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.